Legend Biotech’s CEO stepped down without warning, while Sarepta has appointed a biopharma veteran to take the company forward.
HTX-001 has not received approval from the FDA, European Medicines Agency, or any other regulatory authority.
The deal grants CORE Biomedicine rights to develop and commercialise cancer therapies.
If approved, Apnimed’s lead candidate oxnimbi would become the first pill to break onto the OSA market fraught with unmet needs.
BioMarin and n-Lorem will carry out preclinical studies and jointly select a lead candidate for trials.
The transaction is expected to close in the third quarter of 2026.
